"CRISPR-Cas has revolutionized genome editing by allowing researchers to remove, alter, or add sections of the DNA sequence. By performing large scale functional genomics screens with CRISPR-Cas, scientists can identify and validate drug targets at a much faster rate. Genome editing is now part of almost every step in the drug discovery pipeline, from target identification and its validation to mechanistic studies in relevant disease models to therapeutic genome editing and disease diagnosis. Genome Editing in Drug Discovery offers comprehensive coverage of the revolution CRISPR-Cas has brought to genome editing and its impact on drug discovery. Ideal for academics, researchers, and professionals in the pharmaceutical industry; this book helps readers create better disease models, assess the safety and efficacy of drugs, discover new targets, and develop next-generation diagnostics for disease-related genes. This book provides a historical prospective on genome editing, discusses the general approaches used to make disease models, and offers practical suggestions as the technology advances"-- Provided by publisher.